Sagimet Biosciences Inc. income statement SGMT

Annual Quarterly

It recorded a net loss of $51.0 million. Diluted earnings per share were -$1.58.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Revenue
—
—
2
Research and development
39
+1.6%
38
+94.4%
20
Selling, general and administrative
18
+11.4%
16
+23.5%
13
Operating income
-57
-4.5%
-54
-77.1%
-31
Income tax
0
—
—
Net income
-51
-12.0%
-46
-63.5%
-28
Basic EPS
-1.58
-9.0%
-1.45
+45.5%
-2.66
Diluted EPS
-1.58
-9.0%
-1.45
+45.5%
-2.66
Weighted average shares, basic
32
+3.2%
31
+199.7%
10
Weighted average shares, diluted
32
+3.2%
31
+199.7%
10
Margins
Operating margin
—
—
-1,537.00%
Profit margin
—
—
-1,393.80%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SGMT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Foster City, CA
SEC filer status
, Emerging growth company
SEC CIK
1400118
Former names
3-V Biosciences, Inc. (until Feb 25, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.